Centene Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNC research report →
Range $69 – $90
Price Chart
About the company
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans.
- CEO
- Sarah McGinty London
- IPO
- 2001
- Employees
- 61,100
- HQ
- St. Louis, MO, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive multi-month uptrend and remains well above its 200-day average of 56.79, with the 50-day at 67.23 still trending above the long average. It is also trading near the upper end of its 52-week range, which keeps the regime tilted bullish unless momentum breaks down.
Street sentiment is cautiously positive: the consensus rating is Buy, with 27 buys, 16 holds, and 1 sell. The average target sits at 77.44, above the current share price, and recent revisions have leaned higher, including multiple target raises and a fresh 90 target, even as most firms stay at Hold/Overweight.
The earnings profile favors another solid report, with Centene beating EPS in 7 of the last 8 quarters. Next-year EPS estimates have stepped up to 5.57 from a 2.91 TTM base, so shareholders should watch whether margin discipline and medical cost trends support that jump.
The pattern is mixed but leans negative on discretionary activity. Two large open-market sales by the general counsel stand out, while most other filings are award, vesting, or in-kind compensation flows that are less informative; no meaningful insider buying offsets those sales.
Profitability is modest but improving at scale, with a 1.92% operating margin and 0.81% net margin on 2025 results. Growth is still muted on revenue at 0.2% YoY, but cash generation is strong, with $5.86 billion of free cash flow and $2.16 billion of net cash.
Centene screens as a lower-margin managed care operator versus the best-run peers, but it compensates with strong cash flow and a large government-program footprint. At about 28.8x earnings, the valuation is not cheap for the sector, though it remains below the higher end of analyst targets.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.58B
- P/E
- 21.55
- Fwd P/E
- 12.10
- PEG
- 0.19
- P/S
- 0.15
- P/B
- 1.42
- EV/EBITDA
- 6.98
- Div Yield
- 0.00%
- Gross Margin
- 20.18%
- Op Margin
- 0.50%
- Net Margin
- 0.72%
- ROE
- 6.78%
- ROIC
- 1.91%
Latest fiscal year · YoY change
- Revenue
- $194.78B+19.4%
- Gross Profit
- $23.83B+41.6%
- Op Income
- $-7,618,375,000
- Net Income
- $-6,673,000,000-301.9%
- EPS
- $-13.61-315.0%
- OCF Growth
- +3203.9%
- FCF Growth
- +981.8%
- 52W High
- $78.08
- 52W Low
- $31.63
- 50D MA
- $67.46
- 200D MA
- $57.18
- Beta
- 1.08
- RSI (14)
- 43
- Avg Volume
- 5.03M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Centene beat third-quarter expectations on stronger Medicare and Marketplace performance, raised 2026 EPS guidance above $5.20, and outlined improving momentum into 2027 despite Medicaid and policy-related uncertainty.· October 27, 2026
- Q3 adjusted diluted EPS was $0.58 on $45.1 billion of premium and service revenue; consolidated HBR was 92.7%, both better than expected.
- Medicaid was stable with a 93.6% HBR, membership down 5.0% year to date to 11.9 million, and full-year Medicaid HBR guidance held at about 93.5%.
- Medicare outperformed, with management now expecting Medicare Advantage breakeven in 2026 a year earlier than planned and PDP pretax margin in the mid- to high 3% range.
- Marketplace was stronger than expected; full-year pretax margin is now expected at the top of the prior 4.5% to 5.0% range, helped by underlying trend and reserve updates.
- Company raised full-year 2026 adjusted EPS guidance to more than $5.20 from more than $4.80 and said it expects to grow earnings in 2027 from that revised base.
Centene reported Q3 adjusted diluted EPS of $0.58 and premium and service revenue of $45.1 billion. Consolidated HBR was 92.7%, while the Medicaid HBR was 93.6% and the Medicare segment HBR was 93.8%. Full-year 2026 adjusted EPS guidance was raised to more than $5.20 per diluted share from more than $4.80. Management also said 2026 Medicaid HBR is expected to be about 93.5%, Medicaid membership is expected to be down 8% to 9% for the year, Marketplace pretax margin is expected at the top of the prior 4.5% to 5.0% range, PDP pretax margin is expected in the mid- to high 3% range, and the company still expects about $1.5 billion of investment and other income. For 2027, management said it expects earnings growth but did not give formal guidance; it said more detail will come with February guidance.
Sarah London framed the quarter as evidence that Centene is gaining momentum across core lines of business and entering 2027 with improving fundamentals. She emphasized Medicaid rate conversations, work-requirement implementation readiness, and signs of stabilization in behavioral health and home health trends, while also highlighting Medicare turnaround progress, Marketplace margin recovery, and the company’s ability to absorb policy and program-integrity changes. Her tone was constructive and confident, though she repeatedly noted that 2027 visibility is still partial.
Drew Asher focused on the financial beat and the drivers behind the raised outlook: stronger Medicare and Marketplace results, plus lower interest expense. He cited $45.1 billion of premium and service revenue, $0.58 adjusted EPS, a 92.7% consolidated HBR, SG&A of 6.5% in Q3 versus 7.0% a year ago, and cash flow used by operations of $3.7 billion in the quarter after paying out more than $3 billion of Medicaid pass-through payments; year-to-date operating cash flow was $4.3 billion. He said total debt is $15.0 billion, down from $18.5 billion at year-end 2024, with a debt-to-cap ratio of 41.1%, and reiterated the $1.5 billion investment and other income assumption. He also laid out 2027 bridge items, including Medicaid rate/acuity, better Marketplace margin, Medicare Advantage moving from breakeven to better than breakeven, PDP growth, and a lower consolidated SG&A rate.
Analysts focused on Medicaid rate-setting and how states are handling work requirements, with management saying January 1 cohorts are showing positive engagement, more explicit draft-rate provisions, and better data support than during prior redeterminations. Questions also centered on Marketplace margin durability and the IDR reserve catch-up, and Asher said the adjustment was largely a Q3 catch-up that should not recur in Q4, while underlying marketplace strength supports the top end of the 4.5% to 5.0% margin range. Other questions covered G&A savings, PDP margin reset, and Medicaid 2027 acuity risk; management said cost actions should lower SG&A next year, PDP margins will likely reset closer to a 2% to 3% opening expectation, and the biggest Medicaid risk remains any dislocation between rate and acuity as work requirements roll out.
The call showed multiple businesses outperforming expectations at once: Medicare is ahead of plan, Marketplace margin recovery is stronger than expected, and Medicaid trends appear more stable than feared. Management also pointed to lower debt, improving SG&A, and early signs that state rate setting may better reflect acuity shifts, which supports the case for earnings growth into 2027.
Management still sees meaningful uncertainty around 2027 Medicaid work-requirement impacts, including the risk of a mismatch between rates and acuity as memberships roll off. Marketplace results included reserve updates and program-integrity effects that may create noise, while PDP margins are expected to reset lower from the unusually strong 2026 level. Centene also flagged lower 2027 Medicaid membership, an exit from Health Net commercial group business, and only partial visibility into January 1 rates and open-enrollment outcomes.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.2%
- Shares Outstanding
- 495.07M
- Float Shares
- 486.26M
of shares held by institutions
1,067 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CNC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Sep 4, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 10, 26 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Aug 8, 25 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Apr 14, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 5, 25 | Filing → |
| Val HoyleHouse · OR04 | Buy | Oct 29, 24 | Filing → |
| Tim MooreHouse · NC14 | Sell | Aug 18, 25 | Filing → |
| Tim MooreHouse · NC14 | Buy | Aug 8, 25 | Filing → |
| Tim MooreHouse · NC14 | Buy | Aug 7, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 25, 25 | Filing → |
| Tim MooreHouse · NC14 | Buy | Jul 22, 25 | Filing → |
| Tim MooreHouse · NC14 | Buy | Jul 14, 25 | Filing → |
| Tim MooreHouse · NC14 | Buy | Jul 21, 25 | Filing → |
| Tim MooreHouse · NC14 | Buy | Jul 18, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 56.98M | ▲ 190.33K |
| Blackrock, Inc. | 44.75M | ▲ 3.30M |
| Vanguard Capital Management LLC | 32.33M | ▲ 852.55K |
| Aqr Capital Management LLC | 31.40M | ▲ 2.72M |
| State Street Corp | 23.09M | ▲ 1.13M |
| Vanguard Portfolio Management LLC | 22.48M | ▲ 127.79K |
| Geode Capital Management, LLC | 14.12M | ▲ 812.23K |
| Invesco Ltd. | 13.61M | ▲ 2.43M |
| Ameriprise Financial Inc | 12.16M | ▼ 257.33K |
| Victory Capital Management Inc | 10.94M | ▲ 5.06M |
| Morgan Stanley | 9.97M | ▼ 78.53K |
| Price T Rowe Associates Inc | 8.02M | ▼ 680.78K |
Held by 1,972 ETFs
Biggest fund positions in CNC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | Carson Michael A | other | 7,130 |
| Sep 30, 26 | Tyler Lauren M | other | 482 |
| Sep 30, 26 | TANJI KENNETH | other | 603 |
| Sep 30, 26 | Samuels Theodore R. II | other | 583 |
| Sep 30, 26 | EPPINGER FREDERICK H | other | 864 |
| Sep 30, 26 | COUGHLIN CHRISTOPHER J | other | 583 |
| Sep 15, 26 | PIENKOS THEODORE J | other | 1,092 |
| Aug 26, 26 | KOSTER CHRISTOPHER | sell | 56,500 |
| Aug 18, 26 | KOSTER CHRISTOPHER | sell | 47,603 |
| Jul 28, 26 | DIAZ PAUL J | other | 2,771 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CNC coverage
Recent articles, reports, and earnings notes.

Centene (CNC): Recovery Story With Earnings Volatility
Centene is showing real margin-recovery progress after a difficult 2025, but Medicaid, Marketplace, and Medicare cost pressure still make this a Hold. Q1 2026 results and raised guidance support the turnaround, though the stock already trades near consensus value.

Managed care's rebound looks real, but the easy bull case is early
Health insurers are finally showing signs that the medical-cost spike is easing, but that is not the same thing as a clean, durable margin reset across the group. The better trade still looks selective: some operators are stabilizing, while others remain too expensive or too exposed to unresolved Medicare Advantage and Medicaid pressure.

Centene (CNC): Medicaid Margin Recovery Is Gaining Traction
Centene just delivered a strong Q1 2026 beat-and-raise, with improving Medicaid and Medicare margins supporting a recovery thesis. The stock still looks inexpensive versus its earnings power, but execution on medical cost trend remains the key risk.
Want a deeper read on CNC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Carolina Complete Health Connects More Than 600 North Carolinians with Community Health Resources
prnewswire.com · Nov 19
5 HMO Stocks to Watch Amid Sound Membership Base, Tech Innovation
zacks.com · Nov 17
Healthcare Stocks Overtake Tech: 5 Strong Buys Combining Growth And Value
seekingalpha.com · Nov 17
Health Net Providing Special Assistance to Members and Providers Affected by MP18 Fire in Humboldt
prnewswire.com · Nov 16
Why Centene (CNC) is a Top Momentum Stock for the Long-Term
zacks.com · Nov 16
For 75 San Joaquin County Families, Affordable Housing May be Within Reach thanks to Health Net
prnewswire.com · Nov 13
The S&P 500 Has a "Pure Value" Version. RPV Gives Its Cheapest Stocks the Biggest Weights
247wallst.com · Nov 13
Here's Why Centene (CNC) is a Strong Value Stock
zacks.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 18, 2026 · Live quote · Not investment advice